Influence of Oxa-Nano-Liposome on the Drug Resistance of Gastric Cancer Cells Under p53-Mediated Autophagy

Abstract

The influence of oxaliplatin (Oxa)-nano-liposomes on the drug resistance of gastric cancer cells (GCCs) and the role of p53-mediated autophagy in this process were investigated in this research. Oxa-nano-liposomes were prepared and their quality was evaluated. GCCs treated with Oxa-nano-liposomes were selected and rolled into a negative control (NC) group (cells+ culture medium), a positive control (PC) group (standard Oxa-nano-liposome), and a Oxa-nano-liposome sample group. Cell inhibition rates (IRs) at changeable drug concentrations (DCs) were compared and analyzed. Furthermore, levels of p53 and autophagy-related proteins (ARPs) (such as LC3-II and p62) in the cells were assessed using Western blotting. The results indicated that Oxa-nano-liposomes prepared (Oxa):natural soy phospholipids (NSP):cholesterol:polyethylene glycol (PEG) 2000 = 1:2:1:1 exhibited the best performance. The Oxa-nano-liposome sample group exhibited a higher cell IR to the NC group, showing a great difference (P <0.05). Additionally, the Oxa-nano-liposome sample group demonstrated superior efficacy compared to the PC group. With increasing DC, p53 and LC3-II were upshifted, while p62 was downshifted. In conclusion, Oxa-nano-liposomes effectively inhibited the growth of GCCs, exhibited improved efficacy, and contributed to reducing drug resistance in GCCs towards Oxa-nano-liposomes. Therefore, the Oxa-nano-Liposomes hold significant potential for clinical application. Moreover, p53 regulated the cellular autophagy, enhancing autophagic activity of GCCs.